A new look at an old drug for the treatment of cancer cachexia: Megestrol acetateARGILES, Josep M; ANGUERA, Anna; STEMMLER, Britta et al.Clinical nutrition (Edinburgh). 2013, Vol 32, Num 3, pp 319-324, issn 0261-5614, 6 p.Article

Insulin and cancer (review)ARGILES, Josep M; LOPEZ-SORIANO, Francisco J.International journal of oncology. 2001, Vol 18, Num 4, pp 683-687, issn 1019-6439Article

Plasma from pregnant rats has anti-tumoural activityCARBO, Neus; LOPEZ-SORIANO, Francisco J; ARGILES, Josep M et al.Oncology reports. 2004, Vol 12, Num 4, pp 885-887, issn 1021-335X, 3 p.Article

Therapeutic potential of interleukin-15 : a myokine involved in muscle wasting and adiposityARGILES, Josep M; LOPEZ-SORIANO, Francisco J; BUSQUETS, Silvia et al.Drug discovery today. 2009, Vol 14, Num 3-4, pp 208-213, issn 1359-6446, 6 p.Article

Novel approaches to the treatment of cachexiaARGILES, Josep M; LOPEZ-SORIANO, Francisco J; BUSQUETS, Silvia et al.Drug discovery today. 2008, Vol 13, Num 1-2, pp 73-78, issn 1359-6446, 6 p.Article

Les facteurs cataboliques du cancer: données récentes = New insights in catabolic mediators in cancerARGILES, Josep M; DESCOMBES, Patricia; LOPEZ-SORIANO, Francisco J et al.Nutrition clinique et métabolisme (Paris). 2002, Vol 16, Num 1, pp 14-25, issn 0985-0562Article

Anti-inflammatory therapies in cancer cachexiaARGILES, Josep M; BUSQUETS, Sílvia; LOPEZ-SORIANO, Francisco J et al.European journal of pharmacology. 2011, Vol 668, issn 0014-2999, S81-S86, SUP1Conference Paper

Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatomaMEIJSING, Bas; CARBO, Neus; LOPEZ-SORIANO, Francisco J et al.Cancer letters. 2002, Vol 188, Num 1-2, pp 53-58, issn 0304-3835, 6 p.Article

Catabolic mediators as targets for cancer cachexiaARGILES, Josep M; MOORE-CARRASCO, Rodrigo; BUSQUETS, Silvia et al.Drug discovery today. 2003, Vol 8, Num 18, pp 838-844, issn 1359-6446, 7 p.Article

Myostatin: more than just a regulator of muscle massARGILES, Josep M; ORPI, Marcel; BUSQUETS, Silvia et al.Drug discovery today. 2012, Vol 17, Num 13-14, pp 702-709, issn 1359-6446, 8 p.Article

Antiproteolytic effects of plasma from hibernating bears : A new approach for muscle wasting therapy?FUSTER, Gemma; BUSQUETS, Silvia; ALMENDRO, Vanessa et al.Clinical nutrition (Edinburgh). 2007, Vol 26, Num 5, pp 658-661, issn 0261-5614, 4 p.Article

Mediators involved in the cancer anorexia-cachexia syndrome : past, present, and futureARGILES, Josep M; BUSQUETS, Silvia; GARCIA-MARTINEZ, Cèlia et al.Nutrition (Burbank, Los Angeles County, Calif.). 2005, Vol 21, Num 9, pp 977-985, issn 0899-9007, 9 p.Article

TNF-α modulates cytokine and cytokine receptors in C2C12 myotubesALVAREZ, Belén; QUINN, Lebris S; BUSQUETS, Silvia et al.Cancer letters. 2002, Vol 175, Num 2, pp 181-185, issn 0304-3835Article

Hepatic transport of gluconeogenic substrates during tumor growth in the ratBINK, Hugo; CARBO, Neus; FELIPE, Antonio et al.Cancer investigation. 2001, Vol 19, Num 3, pp 248-255, issn 0735-7907Article

BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing ratsIRMINGER-FINGER, Irmgard; BUSQUETS, Silvia; CALABRIO, Fabrice et al.Oncology reports. 2006, Vol 15, Num 6, pp 1425-1428, issn 1021-335X, 4 p.Article

Roles of skeletal muscle and peroxisome proliferator- activated receptors in the development and treatment of obesityLOPEZ-SORIANO, Joaquin; CHIELLINI, Chiara; MAFFEI, Margherita et al.Endocrine reviews. 2006, Vol 27, Num 3, pp 318-329, issn 0163-769X, 12 p.Article

Direct effects of tumor necrosis factor α (TNF-α) on murine skeletal muscle cell lines. Bimodal effects on protein metabolismALVAREZ, Belén; QUINN, Lebris S; BUSQUETS, Silvia et al.European cytokine network (Montrouge). 2001, Vol 12, Num 3, pp 399-410, issn 1148-5493Article

Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wastingOLIVAN, Mireia; BUSQUETS, Silvia; FIGUERAS, Maite et al.Clinical nutrition (Edinburgh). 2011, Vol 30, Num 1, pp 33-37, issn 0261-5614, 5 p.Article

Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of β₂-adrenergic agonistsFUSTER, Gemma; BUSQUETS, Silvia; AMETLLER, Elisabet et al.Cancer research (Baltimore). 2007, Vol 67, Num 13, pp 6512-6519, issn 0008-5472, 8 p.Article

Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogeneCOSTELLI, Paola; CARBO, Neus; BUSQUETS, Silvia et al.Cancer letters. 2003, Vol 200, Num 2, pp 153-160, issn 0304-3835, 8 p.Article

Sepsis induces DNA fragmentation in rat skeletal muscleALMENDRO, Vanessa; CARBO, Neus; BUSQUETS, Silvia et al.European cytokine network (Montrouge). 2003, Vol 14, Num 4, pp 256-259, issn 1148-5493, 4 p.Article

PATTERNS OF GENE EXPRESSION IN MUSCLE AND FAT IN TUMOR-BEARING RATS: EFFECTS OF CRF2R AGONIST ON CACHEXIAARGILES, Josep M; FONTES-OLIVEIRA, Cibely Cristine; VARBANOV, Alex et al.Muscle & nerve. 2010, Vol 42, Num 6, pp 936-949, issn 0148-639X, 14 p.Article

The AP-1/NF-κB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexiaMOORE-CARRASCO, Rodrigo; BUSQUETS, Silvia; ALMENDRO, Vanessa et al.International journal of oncology. 2007, Vol 30, Num 5, pp 1239-1245, issn 1019-6439, 7 p.Article

Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexiaDEJONG, Cornelis H. C; BUSQUETS, Sylvia; MOSES, Alastair G. W et al.Oncology reports. 2005, Vol 14, Num 1, pp 257-263, issn 1021-335X, 7 p.Article

Effects of the PPARy agonist GW1929 on muscle wasting in tumour-bearing miceMOORE-CARRASCO, Rodrigo; FIGUERAS, Maite; AMETLLER, Elisabet et al.Oncology reports. 2008, Vol 19, Num 1, pp 253-256, issn 1021-335X, 4 p.Article